Senseonics Holdings Files Proxy Statement

TL;DR

Senseonics Holdings (SENS) filed its proxy statement, shareholders need to pay attention to upcoming votes.

AI Summary

Senseonics Holdings, Inc. filed a Definitive Proxy Statement (DEFA14A) on December 9, 2024. The filing concerns the company's proxy materials, indicating it is seeking shareholder approval or providing information related to upcoming shareholder meetings. The company, previously known as ASN Technologies, Inc., is incorporated in Delaware and headquartered in Germantown, MD.

Why It Matters

This filing is important for shareholders as it contains information about how they can vote on company matters and details about the company's governance and upcoming decisions.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEFA14A) that provides information to shareholders and does not inherently represent a new risk event.

Key Players & Entities

• Senseonics Holdings, Inc. (company) — Registrant
• ASN Technologies, Inc. (company) — Former company name
• 20451 SENECA MEADOWS PARKWAY (location) — Company business and mailing address
• Germantown, MD (location) — Company headquarters

FAQ

Key Financial Figures

• $22 million — l net revenue guidance of approximately $22 million Brian Hansen, President of Ascensia&r

Filing Documents

• tm2430569d1_defa14a.htm (DEFA14A) — 31KB
• tm2430569d1_defa14aimg001.jpg (GRAPHIC) — 4KB
• 0001104659-24-126777.txt ( ) — 37KB

Forward Looking Statements

Forward Looking Statements Any statements in this press release about the expectations regarding the success of the commercial product launch of Eversense 365, trends of interest in, and market acceptance and adoption of, Eversense 365 by patients and prescribers, revenue expectations, product development plans and/or growth of Eversense, the potential implementation of the proposed reverse stock split and the potential that the reverse stock split may make the company’s stock more appealing to institutional investors, and other statements containing the words "believe," “expect,” “intend,” “may,” “projects,” “will,” “planned,” and similar expressions, constitute forward-looking indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the new product launch and ongoing commercialization of Eversense 365, uncertainties inherent in the reliance on the commercialization efforts and investment of Ascensia and its commercial initiatives, uncertainties in prescriber and patient decisions and responses to new technology or initiatives, uncertainties in insurer, regulatory and administrative processes and decisions, uncertainties inherent in the development and registration of new technology, uncertainties in the development of and competition in the overall CGM market, the potential inability to receive requisite stockholder approval of the proposed reverse stock split, the risk that the share price resulting from a reverse stock split may not attract institutional or other investors, may not satisfy the investing guidelines of these investors, or otherwise may not result in increased investor interest in Senseonics’ stock or improved trading liquidity in the company’s stock

View Full Filing

View this DEFA14A filing on SEC EDGAR